

Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)

Technology appraisal guidance

Published: 14 September 2022

www.nice.org.uk/guidance/ta822

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of melphalan for treating haematological diseases before allogeneic haematopoietic stem cell transplant. This is because ADIENNE has confirmed that it does not intend to make an evidence submission for the appraisal because it does not represent a commercially viable option for them to pursue.

Information

If NHS organisations wish to consider melphalan for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4742-3

Accreditation

